As of 2025-07-09, the Relative Valuation of Recursion Pharmaceuticals Inc (RXRX) is (19.09) USD. This relative valuation is based on P/E multiples. With the latest stock price at 5.36 USD, the upside of Recursion Pharmaceuticals Inc based on Relative Valuation is -456.1%.
The range of the Relative Valuation is (18.69) - (26.50) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 18.7x | 13.3x |
| Forward P/E multiples | 12.8x - 21.3x | 13.7x |
| Fair Price | (18.69) - (26.50) | (19.09) |
| Upside | -448.7% - -594.4% | -456.1% |
| Date | P/E |
| 2025-07-08 | -3.79 |
| 2025-07-07 | -3.49 |
| 2025-07-03 | -3.73 |
| 2025-07-02 | -3.68 |
| 2025-07-01 | -3.63 |
| 2025-06-30 | -3.58 |
| 2025-06-27 | -3.56 |
| 2025-06-26 | -3.82 |
| 2025-06-25 | -3.65 |
| 2025-06-24 | -3.69 |
| 2025-06-23 | -3.42 |
| 2025-06-20 | -3.56 |
| 2025-06-18 | -3.61 |
| 2025-06-17 | -3.42 |
| 2025-06-16 | -3.54 |
| 2025-06-13 | -3.48 |
| 2025-06-12 | -3.66 |
| 2025-06-11 | -3.82 |
| 2025-06-10 | -3.85 |
| 2025-06-09 | -3.80 |
| 2025-06-06 | -3.88 |
| 2025-06-05 | -3.23 |
| 2025-06-04 | -3.47 |
| 2025-06-03 | -3.10 |
| 2025-06-02 | -3.09 |
| 2025-05-30 | -2.96 |
| 2025-05-29 | -3.15 |
| 2025-05-28 | -3.11 |
| 2025-05-27 | -3.10 |
| 2025-05-23 | -2.89 |
| 2025-05-22 | -2.93 |
| 2025-05-21 | -2.90 |
| 2025-05-20 | -3.22 |
| 2025-05-19 | -3.19 |
| 2025-05-16 | -3.22 |
| 2025-05-15 | -3.01 |
| 2025-05-14 | -3.05 |
| 2025-05-13 | -3.19 |
| 2025-05-12 | -3.28 |
| 2025-05-09 | -3.06 |
| 2025-05-08 | -3.10 |
| 2025-05-07 | -2.96 |
| 2025-05-06 | -2.94 |
| 2025-05-05 | -3.36 |
| 2025-05-02 | -4.03 |
| 2025-05-01 | -3.89 |
| 2025-04-30 | -3.95 |
| 2025-04-29 | -4.05 |
| 2025-04-28 | -4.13 |
| 2025-04-25 | -4.05 |